Lataa...
Diffuse pulmonary lymphangiomatosis treated with bevacizumab
Diffuse pulmonary lymphangiomatosis (DPL) is a rare disease caused by uncontrolled lymphatic vessel proliferation resulting in respiratory dysfunction. Lymphatic vessel growth is influenced by vascular endothelial growth factor (VEGF). It has been shown that bevacizumab, a monoclonal antibody to VEG...
Tallennettuna:
| Julkaisussa: | Respirol Case Rep |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley & Sons, Ltd
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6260917/ https://ncbi.nlm.nih.gov/pubmed/30510764 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.384 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|